Perspectives on informative Bayesian methods in pediatrics-Reference-Cited by-同舟云学术

Perspectives on informative Bayesian methods in pediatrics

Published:2023-01-29 Issue:6 Volume:33 Page:830-843
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Travis James¹,Rothmann Mark¹^ORCID,Thomson Andrew²

Affiliation:

1. Office of Biostatistics, Office of Translational Science, Center for the Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

2. Data Analytics and Methods Taskforce, European Medicines Agency, Amsterdam, NL

Funder

no funding associated with the work

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2023.2170405

Reference36 articles.

1. Risks in a Trial of an Innovative Treatment of Duchenne Muscular Dystrophy

2. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

3. Power Priors and Their Use in Clinical Trials

4. Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs

5. EMA Benlysta Assessment report https://www.ema.europa.eu/en/documents/variation-report/benlysta-h-c-2015-ii-0062-epar-assessment-report-variation_en.pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two‐stage randomized clinical trials with a right‐censored endpoint: Comparison of frequentist and Bayesian adaptive designs;Statistics in Medicine;2024-06-06

2. Beyond the Classical Type I Error: Bayesian Metrics for Bayesian Designs Using Informative Priors;Statistics in Biopharmaceutical Research;2024-05-31

3. Robust incorporation of historical information with known type I error rate inflation;Biometrical Journal;2023-12-08

4. Using Bayesian Dynamic Borrowing to Maximize the Use of Existing Data: A Case-Study;Therapeutic Innovation & Regulatory Science;2023-11-01

5. Pediatric needs should be considered early in the clinical development lifecycle;Journal of Biopharmaceutical Statistics;2023-08-08